Polatuzumab vedotin
Polivy (polatuzumab vedotin) is an antibody pharmaceutical. Polatuzumab vedotin was first approved as Polivy on 2019-06-10. It is used to treat large b-cell lymphoma diffuse in the USA. It has been approved in Europe to treat b-cell lymphoma. The pharmaceutical is active against B-cell antigen receptor complex-associated protein beta chain.
| Trade Name | Polivy |
|---|---|
| Common Name | Polatuzumab vedotin |
| Indication | b-cell lymphoma, large b-cell lymphoma diffuse |
| Drug Class | Synthetic analogs of the dolastatin series; monoclonal antibodies: humanized, tumors as target |
